Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.